Aptose Biosciences Inc. 8-K

What Happened
Aptose Biosciences Inc. announced on June 30, 2026 that it completed a statutory plan of arrangement under which Hanmi Purchaser (a Hanmi Pharmaceuticals subsidiary) acquired all outstanding common shares it did not already own. The Court of King’s Bench of Alberta approved the Arrangement on March 31, 2026, and the Arrangement became effective June 30, 2026. Each eligible common share was converted into the right to receive C$2.41 in cash, subject to required withholdings.

Key Details

• Aggregate cash consideration was approximately USD $3,466,470 (C$4,925,362.79) for 2,043,719 common shares not already owned by Hanmi.
• Hanmi already owned 508,710 shares (19.93%) of the 2,552,429 shares outstanding immediately prior to the Effective Time.
• As a result of the transaction, the Company is now a wholly owned subsidiary of the Hanmi Purchasers and there was a change in control.
• All directors resigned as of the Effective Time; the filing states none of the resignations were due to disagreements with management or the board.
• The Company notified the Toronto Stock Exchange of the closing and expects TSX delisting on or about July 3, 2026; Aptose also intends to file Form 15 to terminate or suspend SEC reporting.
• Locust Walk Securities, LLC provided a fairness opinion to the Special Committee in connection with the Arrangement.

Why It Matters
For investors, the filing confirms a completed acquisition and change of control: public shareholders received a fixed cash payment (C$2.41/share), and Aptose will no longer trade on the TSX and expects to suspend U.S. reporting. That means public trading liquidity and ongoing public disclosures from Aptose will cease once delisting and Form 15 filings are complete.